NY-ESO-1-specific TCR-engineered T-cell Immunotherapy for Triple Negative Breast Cancer
Abstract
Triple negative breast cancer (TNBC) is the most aggressive and difficultly treated subtype of metastatic breast cancer, with very limited treatment option due to lack of expression of estrogen receptors (ERs), progesterone receptors (PRs), or human epidermal growth factor receptor 2 (HER2). Cancer immunotherapy is becoming a promising approach for cancer treatment with little or controllable side effect. We hypothesize that treatment of TNBC patients with NY-ESO-1 TCR-transduced T cells is safe and will result in tumor regression and clinical benefits.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1166364
Entities
People
- Jenny Chang
- Rong Wang
Organizations
- Houston Methodist Research Institute